Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples

Clinical Epigenetics

Volumn 6, Issue 1, 2014, Pages

  Stewart, David J ^a   Nunez, Maria I ^b   Jelinek, Jaroslav ^c   Hong, David ^b   Gupta, Sanjay ^b   Aldaz, Marcelo ^d   Issa, Jean Pierre ^c   Kurzrock, Razelle ^e   Wistuba, Ignacio I ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Decitabine; FHIT; FUS1; LINE 1 methylation; PTEN; Tumor suppressor genes; WWOX

Indexed keywords

DECITABINE; DNA; FRAGILE HISTIDINE TRIAD PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA STRUCTURE; FEMALE; FHIT GENE; FUS1 GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG INTERSPERSED NUCLEAR ELEMENT 1; MALE; PRIORITY JOURNAL; PTEN GENE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WWOX GENE;

EID: 84923367056     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/1868-7083-6-13     Document Type: Article

References (51)

1. Oki Y, Aoki E, Issa JP: Decitabine - bedside to bench. Crit Rev Oncol Hematol 2007, 61: 140-152.
2. Ghoshal K, Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 2007, 43: 395-422.
3. Cantor JP, Iliopoulos D, Rao AS, Druck T, Semba S, Han SY, McCorkell KA, Lakshman TV, Collins JE, Wachsberger P, Friedberg JS, Huebner K: Epigenetic modulation of endogenous tumor suppressor expression in lung cancer xenografts suppresses tumorigenicity. Int J Cancer 2007, 120: 24-31.
4. Iliopoulos D, Fabbri M, Druck T, Qin HR, Han SY, Huebner K: Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res 2007, 13: 268-274.
5. Phuong NT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, Ahn SG, Yoon JH, Kang KW: Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat 2011, 130: 73-83.
6. Gravina GL, Biordi L, Martella F, Flati V, Ricevuto E, Ficorella C, Tombolini V, Festuccia C: Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol 2009, 35: 1133-1139.
7. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005, 23: 3948-3956.
8. Stewart DJ, Issa JP, Kurzrock R, Nunez MI, Jelinek J, Hong D, Oki Y, Guo Z, Gupta S, Wistuba II: Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 2009, 15: 3881-3888.
9. Stewart DJ, Nunez MI, Jelinek J, Hong D, Gupta S, Issa JP, Wistuba II, Kurzrock R: Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics 2014, 6(1): 2.
10. Ishii H, Ozawa K, Furukawa Y: Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J Exp Ther Oncol 2003, 3: 291-296.
11. Pichiorri F, Palumbo T, Suh SS, Okamura H, Trapasso F, Ishii H, Huebner K, Croce CM: Fhit tumor suppressor: guardian of the preneoplastic genome. Future Oncol 2008, 4: 815-824.
12. Zhang X, Li HM, Liu Z, Zhou G, Zhang Q, Zhang T, Zhang J, Zhang C: Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J Gastroenterol 2013, 48: 132-143.
13. Paluszczak J, Misiak P, Wierzbicka M, Wozniak A, Baer-Dubowska W: Frequent hypermethylation of DAPK, RARbeta, MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa. Oral Oncol 2011, 47: 104-107.
14. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD: 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 2001, 61: 3581-3585.
15. Ki KD, Lee SK, Tong SY, Lee JM, Song DH, Chi SG: Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J Gynecol Oncol 2008, 19: 117-122.
16. Stephen JK, Chen KM, Raitanen M, Grenman S, Worsham MJ: DNA hypermethylation profiles in squamous cell carcinoma of the vulva. Int J Gynecol Pathol 2009, 28: 63-75.
17. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk YM, Rynditch AV, Vozianov AF: Hypermethylation of the 5‘CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 2008, 265: 250-257.
18. Nunez MI, Ludes-Meyers J, Abba MC, Kil H, Abbey NW, Page RE, Sahin A, Klein-Szanto AJ, Aldaz CM: Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat 2005, 89: 99-105.
19. Cui Z, Lin D, Cheng F, Luo L, Kong L, Xu J, Hu J, Lan F: The role of the WWOX gene in leukemia and its mechanisms of action. Oncol Rep 2013, 29: 2154-2162.
20. Dayan S, O’Keefe LV, Choo A, Richards RI: Common chromosomal fragile site FRA16D tumor suppressor WWOX gene expression and metabolic reprograming in cells. Genes Chromosomes Cancer 2013, 52: 823-831.
21. Aqeilan RI, Croce CM: WWOX in biological control and tumorigenesis. J Cell Physiol 2007, 212: 307-310.
22. Nunez MI, Ludes-Meyers J, Aldaz CM: WWOX protein expression in normal human tissues. J Mol Histol 2006, 37: 115-125.
23. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM: WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 2005, 5: 64.
24. Yang W, Cui S, Ma J, Lu Q, Kong C, Liu T, Sun Z: Cigarette smoking extract causes hypermethylation and inactivation of WWOX gene in T-24 human bladder cancer cells. Neoplasma 2012, 59: 216-223.
25. Guo W, Wang G, Dong Y, Guo Y, Kuang G, Dong Z: Decreased expression of WWOX in the development of esophageal squamous cell carcinoma. Mol Carcinog 2013, 52: 265-274.
26. Pluciennik E, Nowakowska M, Wujcicka WI, Sitkiewicz A, Kazanowska B, Zielińska E, Bednarek AK: Genetic alterations of WWOX in Wilms’ tumor are involved in its carcinogenesis. Oncol Rep 2012, 28: 1417-1422.
27. Baykara O, Demirkaya A, Kaynak K, Tanju S, Toker A, Buyru N: WWOX gene may contribute to progression of non-small-cell lung cancer (NSCLC). Tumour Biol 2010, 31: 315-320.
28. Ji L, Roth JA: Tumor suppressor FUS1 signaling pathway. J Thorac Oncol 2008, 3: 327-330.
29. Demokan S, Chuang AY, Chang X, Khan T, Smith IM, Pattani KM, Dasgupta S, Begum S, Khan Z, Liegeois NJ, Westra WH, Sidransky D, Koch W, Califano JA: Identification of guanine nucleotide-binding protein gamma-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling. Int J Oncol 2013, 42: 1427-1436.
30. da Costa PE, Cavalli LR, Rainho CA: Evidence of epigenetic regulation of the tumor suppressor gene cluster flanking RASSF1 in breast cancer cell lines. Epigenetics 2011, 6: 1413-1424.
31. Hollander MC, Blumenthal GM, Dennis PA: PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 2011, 11: 289-301.
32. Yin L, Cai WJ, Liu CX, Chen YZ, Hu JM, Jiang JF, Li HA, Cui XB, Chang XY, Zhang WJ, Sun K, Li F: Analysis of PTEN methylation patterns in soft tissue sarcomas by MassARRAY spectrometry. PLoS One 2013, 8: e62971.
33. Kuo LT, Kuo KT, Lee MJ, Wei CC, Scaravilli F, Tsai JC, Tseng HM, Kuo MF, Tu YK: Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer 2009, 124: 2872-2879.
34. Shetty PJ, Pasupuleti N, Chava S, Nasaruddin K, Hasan Q: Altered transcription and expression of PTEN in breast tumors: is it regulated by hypermethylation? Breast Dis 2011, 33: 27-33.
35. Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY: Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006, 6: 212.
36. Schondorf T, Ebert MP, Hoffmann J, Becker M, Moser N, Pur S, Göhring UJ, Weisshaar MP: Hypermethylation of the PTEN gene in ovarian cancer cell lines. Cancer Lett 2004, 207: 215-220.
37. Kawaguchi K, Oda Y, Saito T, Takahira T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M: Genetic and epigenetic alterations of the PTEN gene in soft tissue sarcomas. Hum Pathol 2005, 36: 357-363.
38. Hesson LB, Packham D, Pontzer E, Funchain P, Eng C, Ward RL: A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines. Biological Procedures Online 2012, 14: 5.
39. Yu J, Ni M, Xu J, Zhang H, Gao B, Gu J, Chen J, Zhang L, Wu M, Zhen S, Zhu J: Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002, 2: 29.
40. Tamura G: Promoter methylation status of tumor suppressor and tumor-related genes in neoplastic and non-neoplastic gastric epithelia. Histol Histopathol 2004, 19: 221-228.
41. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T, Nephew KP: Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012, 72: 2197-2205.
42. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC Jr: Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011, 117: 1661-1669.
43. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP, Matei DE: A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010, 116: 4043-4053.
44. Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z: p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up. World J Gastroenterol 2011, 17: 2143-2149.
45. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D, Waugh MK: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91: 763-771.
46. Clayman GL, El-Naggar AK, Lippman SM, Henderson YC, Frederick M, Merritt JA, Zumstein LA, Timmons TM, Liu TJ, Ginsberg L, Roth JA, Hong WK, Bruso P, Goepfert H: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998, 16: 2221-2232.
47. Lu C, Stewart DJ, Lee JJ, Ji L, Ramesh R, Jayachandran G, Nunez MI, Wistuba II, Erasmus JJ, Hicks ME, Grimm EA, Reuben JM, Baladandayuthapani V, Templeton NS, McMannis JD, Roth JA: Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS One 2012, 7: e34833.
48. Li W, Deng J, Jiang P, Tang J: Association of 5'-CpG island hypermethylation of the FHIT gene with lung cancer in southern-central Chinese population. Cancer Biol Ther 2010, 10: 997-1000.
49. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH: Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006, 66: 4049-4054.
50. Si J, Boumber YA, Shu J, Qin T, Ahmed S, He R, Jelinek J, Issa JP: Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation. Cancer Res 2010, 70: 6968-6977.
51. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP: A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004, 32: e38.